Back to results
US 11,299,484 B2Granted
Inhibiting fatty acid synthase (FASN)
AssigneeFORMA Therapeutics, Inc.
InventorsMatthew W. Martin, Mary-Margaret Zablocki, Scot Mente, Christopher Dinsmore, Zhongguo Wang, Xiaozhang Zheng
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to inhibitors of FASN. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of FASN. For instance, the disclosure is concerned with compounds and compositions for inhibition of FASN, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of FASN, and methods of synthesis of these compounds.
Claims22
A method for preparing a compound of formula (VII-A):
- or a pharmaceutically acceptable salt thereof, wherein:
- Ring B is phenyl, fused bicyclic 8-10 membered aryl, or fused bicyclic 8-10 membered heteroaryl containing 1-2 heteroatoms independently selected from the group consisting of O, N, and S;
- R1 is 3-membered cycloalkyl optionally substituted with —OH, or 5-membered heterocyclyl containing 1-3 heteroatoms independently selected from the group consisting of O, N, and S;
- each Rd is independently halogen, —CO2H, —OR3, SO2NHCOR3, C1-3 aliphatic, or 5-membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N, and S;
- and
- each R3 is independently hydrogen or C1-3 alkyl;
- comprising:
- treating a compound of formula (A):
- with a compound of formula (B):
- Ar—X (B)
- to afford a compound of formula (C):
- wherein:
- PG is hydrogen or Boc;
- X is halogen;
- and
- Ar is a substituted phenyl, fused bicyclic 8-10 membered aryl, or fused bicyclic 8-10 membered heteroaryl containing 1-2 heteroatoms independently selected from the group consisting of O, N, and S;
- and
- converting the compound of formula (C) to the compound of formula (VII-A), or a pharmaceutically acceptable salt thereof.
15 more elements
Dependencies are inferred from the claim text.